This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

(2) The study only tested one trastuzumab-resistant and one trastuzumab-sensitive cell line. It is unclear whether these findings are applicable to other HER2-positive tumor cell lines, such as ...

that could see the drug being used in advanced breast cancer with even lower levels of the HER2 biomarker. The marketing application for Enhertu (trastuzumab deruxtecan) is based on the results of ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

This crisis has been worsened by the transition from the NHIF to the Social Health Authority (SHA), which has caused widespread disruptions in healthcare services. Be part of an exclusive group of ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Pharmacogenomics. 2013;14(3):15-24.

Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea ...